Newborn SMA mice were treated with a single subcutaneous injection of 40 μg/g (therapeutic dose) or 10 μg/g (low-dose) PMO25 alone or in association with systemic delivery of a single dose of AAV encoding the myostatin propeptide. The gene discussed is MSTN; the disease is proximal spinal muscular atrophy.